{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:31:04Z","timestamp":1789731064482,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273537"],"award-info":[{"award-number":["82273537"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.abd.2023.09.003","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T13:10:34Z","timestamp":1708521034000},"page":"425-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6561-9269","authenticated-orcid":false,"given":"Zi","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9582-902X","authenticated-orcid":false,"given":"Jiangyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2913-1880","authenticated-orcid":false,"given":"Xiaojie","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-210X","authenticated-orcid":false,"given":"Shuang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0256-1229","authenticated-orcid":false,"given":"Jianji","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-4273","authenticated-orcid":false,"given":"Zhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.09.003_bib0005","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/492S52a","article-title":"Immunology: a many layered thing","volume":"492","author":"Ainsworth","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.abd.2023.09.003_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance","volume":"1217","author":"Fife","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.abd.2023.09.003_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.abd.2023.09.003_bib0020","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/s41423-021-00702-y","article-title":"The complex role of PD-L1 in antitumor immunity: a recent update","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0025","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.abd.2023.09.003_bib0035","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s10147-018-1259-6","article-title":"Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update","volume":"23","author":"Nagai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0045","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(15)70103-8","article-title":"Programmed cell death-1 inhibition in lymphoma","volume":"16","author":"Hawkes","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0050","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.abd.2023.09.003_bib0055","first-page":"50","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"10","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.abd.2023.09.003_bib0060","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.abd.2023.09.003_bib0065","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1007\/s00520-020-05707-3","article-title":"Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors","volume":"28","author":"Dougan","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.abd.2023.09.003_bib0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of Different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0075","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors-an overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.abd.2023.09.003_bib0080","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac016","article-title":"Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors","volume":"2","author":"Jfri","year":"2022","journal-title":"Immunother Adv"},{"key":"10.1016\/j.abd.2023.09.003_bib0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40264-020-00907-6","article-title":"Hyperkeratotic skin adverse events induced by anticancer treatments: a comprehensive review","volume":"43","author":"Vastarella","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.abd.2023.09.003_bib0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.abd.2023.02.003","article-title":"Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab","volume":"1","author":"Andrade","year":"2024","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0100","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review","volume":"10","author":"De Bock","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0115","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.09.003_bib0120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0125","first-page":"87","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.abd.2023.09.003_bib0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/DAD.0b013e3181722ef4","article-title":"Pattern analysis of drug-induced skin diseases","volume":"30","author":"Justiniano","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.abd.2023.09.003_bib0135","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.abd.2023.09.003_bib0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.abd.2023.09.003_bib0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0150","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2023.09.003_bib0155","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2478\/v10039-010-0037-0","article-title":"IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis","volume":"55","author":"Glowacka","year":"2010","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.abd.2023.09.003_bib0160","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.2020009417","article-title":"Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.abd.2023.09.003_bib0165","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.2021012186","article-title":"Live or die: PD-L1 delays neutrophil apoptosis","volume":"138","author":"El-Benna","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.abd.2023.09.003_bib0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941071","article-title":"Dendritic cells and macrophages in the pathogenesis of psoriasis","volume":"13","author":"Kamata","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0175","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.abd.2023.09.003_bib0180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0185","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.4049\/jimmunol.177.11.7515","article-title":"Cutting edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation","volume":"177","author":"Takemoto","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0190","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41423-022-00940-8","article-title":"The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry","volume":"19","author":"Zhou","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nri2528","article-title":"Trophic macrophages in development and disease","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nri978","article-title":"Alternative activation of macrophages","volume":"3","author":"Gordon","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0205","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1172\/JCI36150","article-title":"Macrophage diversity in renal injury and repair","volume":"118","author":"Ricardo","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.abd.2023.09.003_bib0210","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/jid.2009.43","article-title":"Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis","volume":"129","author":"Wang","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0215","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0220","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s10875-012-9843-4","article-title":"IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis","volume":"33","author":"Fonseca-Camarillo","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0225","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00011-011-0316-7","article-title":"Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression","volume":"60","author":"Gesser","year":"2011","journal-title":"Inflamm Res"},{"key":"10.1016\/j.abd.2023.09.003_bib0230","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.intimp.2015.07.036","article-title":"Anti-TNF-alpha monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis","volume":"28","author":"Liu","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.abd.2023.09.003_bib0235","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ebiom.2016.10.022","article-title":"Prokineticin 2 plays a pivotal role in psoriasis","volume":"13","author":"He","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.abd.2023.09.003_bib0240","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.4049\/jimmunol.1402550","article-title":"NF-kappaB regulates PD-1 expression in macrophages","volume":"194","author":"Bally","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0245","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1073\/pnas.0809422106","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.abd.2023.09.003_bib0250","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1038\/cti.2017.12","article-title":"The role of PD-1 in regulation of macrophage apoptosis and its subversion by Leishmania donovani","volume":"6","author":"Roy","year":"2017","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0255","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1161\/ATVBAHA.113.300168","article-title":"Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions","volume":"33","author":"Mantovani","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.abd.2023.09.003_bib0260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.abd.2023.09.003_bib0265","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0270","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-019-0772-z","article-title":"Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment","volume":"12","author":"Tian","year":"2019","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.abd.2023.09.003_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20100163","article-title":"Psoriasis: from pathogenesis to novel therapeutic approaches","volume":"120","author":"Monteleone","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.abd.2023.09.003_bib0280","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/168321","article-title":"Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis","volume":"2013","author":"Chong","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.abd.2023.09.003_bib0285","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.abd.2023.09.003_bib0290","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0295","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.abd.2023.09.003_bib0300","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0305","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","article-title":"Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway","volume":"66","author":"Wang","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.abd.2023.09.003_bib0310","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.abd.2023.09.003_bib0315","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.abd.2023.09.003_bib0320","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.abd.2023.09.003_bib0325","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12864-018-4772-0","article-title":"Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics","volume":"19","author":"Street","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.abd.2023.09.003_bib0330","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.abd.2023.09.003_bib0335","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.abd.2023.09.003_bib0340","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/icb.2012.53","article-title":"Notch signaling regulates PD-1 expression during CD8(+) T-cell activation","volume":"91","author":"Mathieu","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.abd.2023.09.003_bib0345","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/539841","article-title":"Notch signaling pathway was involved in regulating programmed cell death 1 expression during sepsis-induced immunosuppression","volume":"2015","author":"Pan","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.abd.2023.09.003_bib0350","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fimmu.2017.00419","article-title":"Notch signaling in T Helper Cell subsets: instructor or unbiased amplifier?","volume":"8","author":"Tindemans","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0355","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/imm.13021","article-title":"Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3(+) regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice","volume":"156","author":"Lin","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.abd.2023.09.003_bib0360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.abd.2023.09.003_bib0365","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0370","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol."},{"key":"10.1016\/j.abd.2023.09.003_bib0375","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/sji.12404","article-title":"Characterization of Th17 and FoxP3(+) treg cells in paediatric psoriasis patients","volume":"83","author":"Zhang","year":"2016","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0380","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clim.2013.06.007","article-title":"Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset","volume":"149","author":"Soler","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0385","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.abd.2023.09.003_bib0390","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1126\/science.1058867","article-title":"Preferential localization of effector memory cells in nonlymphoid tissue","volume":"291","author":"Masopust","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.abd.2023.09.003_bib0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/35065111","article-title":"Visualizing the generation of memory CD4 T cells in the whole body","volume":"410","author":"Reinhardt","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.abd.2023.09.003_bib0400","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T Cells","volume":"11","author":"Tokura","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0410","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41590-022-01229-8","article-title":"Tissue-resident memory CD8(+) T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments","volume":"23","author":"Crowl","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.abd.2023.09.003_bib0415","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1073\/pnas.1322292111","article-title":"Persistence of skin-resident memory T cells within an epidermal niche","volume":"111","author":"Zaid","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.abd.2023.09.003_bib0420","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002231","article-title":"Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade","volume":"9","author":"Banchereau","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.abd.2023.09.003_bib0425","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.abd.2023.09.003_bib0430","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force\u2019 Dermatology for cancer patients\u2019 position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.09.003_bib0435","first-page":"123","article-title":"Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.abd.2023.09.003_bib0440","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12094-018-1953-x","article-title":"Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology","volume":"21","author":"Gravalos","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.abd.2023.09.003_bib0445","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0450","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.abd.2023.09.003_bib0455","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.09.003_bib0460","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1634\/theoncologist.2019-0550","article-title":"Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer","volume":"25","author":"Aso","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.abd.2023.09.003_bib0465","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:51Z","timestamp":1747666851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059624000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0365059624000151"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.09.003","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}